TRENDLINES GROUP: Insights into how it works (from March deals)

steve explains1.16 Trendlines Group Co-Chairman Steve Rhodes taking Singapore analysts and investors on a tour of his company's premises in Israel. NextInsight file photo.TRENDLINES GROUP's workings -- which Singapore investors are not entirely familiar with -- can be understood better through two events that took place last month (March 2016).

These were announced by Trendlines on 1 April.

♦ Magdent Ltd attracts US$800K in investment

Magdent Ltd is one of the 47 start-ups being incubated by Trendlines in Israel.

The Market

The global dental implant market is worth US$4.2 billion and consists of 10 million implants per year.

Magdent focuses on developing a specialized cap for dental implants that utilizes an electromagnetic field to stimulate and improve bone formation surrounding the implant.

Trendlines, for its part, provides the admin support, including accounting, and the physical office, for example.

Most importantly, Trendlines brings investors to Magdent.

New investments are one of the main catalysts for increases in the portfolio value of Trendlines -- and it has been rising every year since Trendlines started life in 2007.

The portfolio value is a key figure that investors pay attention to in Trendlines' financial reports.

Magdent’s product is patented in the United States, has European regulatory certification (CE), and is being marketed in several countries.

Watch this video on how its product works in dental implants -->

♦ LapSpace Medical receives CE Mark for its inflatable retractor

The Market

Over 4 million laparoscopic procedures are performed annually in the US. LapSpace estimates that 50% of these procedures could benefit from its proprietary retractor.

LapSpace Medical, another Trendlines start-up, has developed a device which aids in laparoscopic surgeries.

The product has received the CE Mark, which opens the way for it to be sold in Europe. Earlier, it had received FDA clearance for sale in the US.

The device has been used successfully in more than 50 surgeries and a clinical trial at Johns Hopkins Hospital.

During the procedures, it was discovered that the device is suitable for additional applications which increase the potential market, with over 8 million laparoscopic procedures carried out a year.

Founded in 2011, LapSpace has gone from pure idea to product prototype to clinical trials. The achievement of CE mark and FDA approval are, needless to say, vital milestones that increase its value.

At some point, Trendlines would exit the start-up with a multi-fold return on its investment . The latter, by the way, amounts to US$115,000 in cash and about US$450,000 in services rendered as an incuabtor over two years.

And the Israeli government, which provided US$652,000 in grants, will get its money back.

Watch this video on LapSpace's product -->

TRENDLINES GROUP: Insights into how it works (from March deals)

You may also be interested in: